Granules India Limited

NSE GRANULES.NS

Granules India Limited Gross Profit for the year ending March 31, 2024: USD 284.82 M

Granules India Limited Gross Profit is USD 284.82 M for the year ending March 31, 2024, a 6.18% change year over year. Gross profit is the difference between revenue and the cost of revenue, representing the profit earned from core business operations.

Granules India Limited Gross Profit for the year ending March 31, 2023 was USD 268.24 M, a 15.18% change year over year.
Granules India Limited Gross Profit for the year ending March 31, 2022 was USD 232.88 M, a -2.06% change year over year.
Granules India Limited Gross Profit for the year ending March 31, 2021 was USD 237.77 M, a 45.71% change year over year.
Granules India Limited Gross Profit for the year ending March 31, 2020 was USD 163.18 M, a 19.48% change year over year.

Key data

Date	Gross Profit	Operating Income	EBIT	EBITDA

NSE: GRANULES.NS

Granules India Limited

CEO	Dr. Kandiraju Venkata Sita Ram Rao B.Tech, M.E., Ph.D.
IPO Date	June 20, 2005
Location	India
Headquarters	My Home Hub
Employees	4,057
Sector	Health Care
Industries Pharmaceuticals

Description

Granules India Limited manufactures and sells active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates, and finished dosages (FDs) in India, North America, Europe, Latin America, Africa, the Middle East, and internationally. The company's APIs in various therapeutic categories include anti-retrovirals, anti-hypertensives, anti-histamines, anti-infectives, analgesics, anti-coagulants, anti-fibriotics, and platelet inhibitors. It also offers various FDs, such as tablets, caplets, and press-fit capsules in bulk, blister packs, and bottles; and other specialty products for oncology. The Company also exports its products. Granules India Limited was founded in 1984 and is based in Hyderabad, India.

Key trends

Past 5 years